Unknown

Dataset Information

0

Genetic variation in the transforming growth factor-? signaling pathway and survival after diagnosis with colon and rectal cancer.


ABSTRACT: The transforming growth factor-? (TGF-?) signaling pathway is involved in many aspects of tumorigenesis, including angiogenesis and metastasis. The authors evaluated this pathway in association with survival after a diagnosis of colon or rectal cancer.The study included 1553 patients with colon cancer and 754 patients with rectal cancer who had incident first primary disease and were followed for a minimum of 7 years after diagnosis. Genetic variations were evaluated in the genes TGF-?1 (2 single nucleotide polymorphisms [SNPs]), TGF-? receptor 1 (TGF-?R1) (3 SNPs), smooth muscle actin/mothers against decapentaplegic homolog 1 (Smad1) (5 SNPs), Smad2 (4 SNPs), Smad3 (37 SNPs), Smad4 (2 SNPs), Smad7 (11 SNPs), bone morphogenetic protein 1 (BMP1) (11 SNPs), BMP2 (5 SNPs), BMP4 (3 SNPs), bone morphogenetic protein receptor 1A (BMPR1A) (9 SNPs), BMPR1B (21 SNPs), BMPR2 (11 SNPs), growth differentiation factor 10 (GDF10) (7 SNPs), Runt-related transcription factor 1 (RUNX1) (40 SNPs), RUNX2 (19 SNPs), RUNX3 (9 SNPs), eukaryotic translation initiation factor 4E (eiF4E) (3 SNPs), eukaryotic translation initiation factor 4E-binding protein 3 (eiF4EBP2) (2 SNPs), eiF4EBP3 (2 SNPs), and mitogen-activated protein kinase 1 (MAPK1) (6 SNPs).After adjusting for American Joint Committee on Cancer stage and tumor molecular phenotype, 12 genes and 18 SNPs were associated with survival in patients with colon cancer, and 7 genes and 15 tagSNPs were associated with survival after a diagnosis of rectal cancer. A summary score based on "at-risk" genotypes revealed a hazard rate ratio of 5.10 (95% confidence interval, 2.56-10.15) for the group with the greatest number of "at-risk" genotypes; for rectal cancer, the hazard rate ratio was 6.03 (95% confidence interval, 2.83-12.75).The current findings suggest that the presence of several higher risk alleles in the TGF-? signaling pathway increase the likelihood of dying after a diagnosis of colon or rectal cancer.

SUBMITTER: Slattery ML 

PROVIDER: S-EPMC3476941 | biostudies-literature | 2011 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Genetic variation in the transforming growth factor-β signaling pathway and survival after diagnosis with colon and rectal cancer.

Slattery Martha L ML   Lundgreen Abbie A   Herrick Jennifer S JS   Wolff Roger K RK   Caan Bette J BJ  

Cancer 20110301 18


<h4>Background</h4>The transforming growth factor-β (TGF-β) signaling pathway is involved in many aspects of tumorigenesis, including angiogenesis and metastasis. The authors evaluated this pathway in association with survival after a diagnosis of colon or rectal cancer.<h4>Methods</h4>The study included 1553 patients with colon cancer and 754 patients with rectal cancer who had incident first primary disease and were followed for a minimum of 7 years after diagnosis. Genetic variations were eva  ...[more]

Similar Datasets

| S-EPMC3652588 | biostudies-literature
| S-EPMC4302054 | biostudies-literature
| S-EPMC6770250 | biostudies-literature
| S-EPMC9213724 | biostudies-literature
| S-EPMC3073847 | biostudies-literature
| S-EPMC2796203 | biostudies-literature
| S-EPMC4403665 | biostudies-literature
| S-EPMC3081620 | biostudies-literature
| S-EPMC4476448 | biostudies-literature
| S-EPMC4402428 | biostudies-literature